BVS vs. NVCR, LMAT, EYE, ENOV, CNMD, AORT, CDRE, TNDM, ESTA, and LQDA
Should you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), Artivion (AORT), Cadre (CDRE), Tandem Diabetes Care (TNDM), Establishment Labs (ESTA), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry.
Bioventus vs. Its Competitors
Bioventus (NYSE:BVS) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.
Bioventus has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -26.41%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.
62.9% of Bioventus shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 5.5% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bioventus presently has a consensus target price of $14.33, indicating a potential upside of 109.25%. NovoCure has a consensus target price of $32.83, indicating a potential upside of 83.63%. Given Bioventus' higher probable upside, research analysts clearly believe Bioventus is more favorable than NovoCure.
Bioventus has higher earnings, but lower revenue than NovoCure. Bioventus is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.
In the previous week, NovoCure had 9 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for NovoCure and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.11 beat NovoCure's score of 0.52 indicating that Bioventus is being referred to more favorably in the media.
Summary
Bioventus beats NovoCure on 10 of the 15 factors compared between the two stocks.
Get Bioventus News Delivered to You Automatically
Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bioventus Competitors List
Related Companies and Tools
This page (NYSE:BVS) was last updated on 7/3/2025 by MarketBeat.com Staff
Free BVS Stock Alerts